Video
Dr. Cohen on Diversifying the Patient Population for a Clinical Trial in Medullary Thyroid Cancer
Author(s):
Roger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).
Roger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).
MTC is a rare disease, accounting for 1% to 2% of thyroid cancer cases. The prognosis for these patients is poor, and there are few treatment options for those with relapsed/refractory disease.
Investigators leading clinical trials must go the extra mile to recruit diverse patient populations and the challenge is even greater for those exploring rare cancers. Here, Dr. Cohen explains the steps Penn is taking to recruit the broadest variety of patients.
